New research underscores the critical role of lipid profiles in men's health, revealing that higher atherogenic index levels may not only signal heart trouble but also significantly increase the ...

A major component of the insulin resistance syndrome is dyslipidemia. Alterations in serum lipid levels can be worsened by insulin resistance and represent a leading risk factor for the ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

Fibrates are widely prescribed agonists of transcription factor peroxisome proliferator-activated receptor (PPAR)-α, and are used to treat patients with atherogenic dyslipidemia. These drugs ...

ALG-055009 dose groups met the primary endpoint with statistically significant reductions in liver fat at Week 12 as measured ...

Cardiovascular-kidney-metabolic (CKM) syndrome may affect 90% of U.S. adults, new research finds. CKM is a cluster of ...

In the trial, doses ranging from 0.5mg to 0.9mg of ALG-055009 led to notable median relative reductions in liver fat.

The investigational treatment was actually tied to a lower incidence of diarrhea when compared to placebo. ALG-055009 was ...

This review summarizes the current investigations that confirm the significance of liver fibrosis (LF) as an independent ...

The US FDA has granted breakthrough therapy designation to Arrowhead Pharmaceuticals’ plozasiran, a RNA interference (RNAi) therapeutic.